A French medical device company spent 87 working days registering their China entity in 2026 — nearly double the standard 45-day WFOE timeline. The reason: medical devices fall under the Negative List (负面清单, fùmiàn qīngdān) for foreign investment, triggering additional government approvals that add 4–6 weeks. Here’s the real timeline, the real costs, and what every foreign healthcare company should know before starting.
Background
MediLyon SAS is a Lyon-based manufacturer of Class II and Class III surgical imaging devices with €42 million in annual revenue. China represented 8% of sales through a local distributor, but the company’s leadership wanted direct market access — particularly to China’s rapidly expanding private hospital sector, which grew from 21,000 facilities in 2020 to an estimated 29,000 in 2026 according to National Health Commission data. Without a China entity, MediLyon couldn’t participate in provincial hospital tenders directly, couldn’t hold NMPA (National Medical Products Administration, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) registration certificates in their own name, and had zero control over their distributor’s pricing and channel strategy.
The company targeted Shanghai’s Zhangjiang Hi-Tech Park (张江高科技园区, Zhāngjiāng Gāokējì Yuánqū), China’s largest life sciences cluster with over 1,500 biomedical companies and a dedicated medical device regulatory service center. For a walkthrough of the standard registration steps, see our 7-step WFOE registration guide.
The Challenge
Medical devices appear on China’s Special Administrative Measures for Foreign Investment Access — the Negative List. As of the 2025 edition (effective January 2026), medical devices are classified as a “restricted” sector, not “prohibited.” A foreign company CAN establish a WFOE, but it must obtain pre-approval from the industry regulator (NMPA) BEFORE the standard AMR company registration process can begin.
This creates a two-gate registration sequence that most first-time applicants misunderstand. Gate 1 is NMPA pre-approval: the company must submit its product registration certificates, quality management system documentation (ISO 13485 or equivalent), and a declaration that the proposed China entity’s business scope is limited to products already registered with NMPA. Gate 1 took MediLyon 31 working days — and it was the most unpredictable phase of the entire registration.
Gate 2 is the standard AMR registration, but with enhanced documentation requirements. The AMR required three additional items beyond the standard WFOE package: (a) the NMPA pre-approval letter, (b) a declaration from the legal representative confirming awareness of ongoing regulatory obligations (不良反应监测, bùliáng fǎnyìng jiāncè — adverse event monitoring), and (c) evidence of a qualified person — a Chinese national with a medical or pharmaceutical degree — on the company’s proposed payroll.
The personnel requirement was the hidden cost driver. MediLyon had planned to staff the Shanghai entity with one expatriate general manager and two local sales staff. The “qualified person” requirement meant hiring a fourth person — a licensed pharmacist with NMPA regulatory experience — before the company even had revenue. Market rate for this role in Shanghai: RMB 35,000–50,000/month ($4,800–$6,900), adding $58,000–$83,000 to the first-year cost structure before a single device was sold.
The Solution
MediLyon engaged a Shanghai law firm specializing in life sciences foreign investment — not a general corporate services agency. This distinction mattered. The law firm had handled 14 medical device WFOE registrations in 2025 and understood both the NMPA gate and the AMR’s enhanced documentation expectations. Standard corporate service agencies (the type that handle 85% of general WFOE registrations) often learn the medical device workflow mid-process, which adds weeks to the timeline.
Here’s the 87-day timeline in detail:
- NMPA pre-approval preparation (Days 1–14): The law firm compiled MediLyon’s EU MDR certificates (recognized by NMPA under the 2024 EU-China medical device mutual recognition agreement), ISO 13485 certification, product technical files for 12 Class II devices, and a Chinese-language summary of clinical data. The NMPA submission package was 287 pages — the largest single document bundle in the entire registration.
- NMPA review (Days 15–45): The NMPA Shanghai office (a pilot site for accelerated foreign medical device review) processed the application in 21 working days, plus a 5-working-day supplementary review period triggered by a labeling question on one device. Total: 26 working days. The national average for NMPA pre-approval on foreign medical device WFOEs, according to the law firm’s internal data, is 35–45 working days — Shanghai’s pilot program cut 10–15 days off the standard timeline.
- AMR business license application (Days 46–62): The Shanghai AMR accepted the NMPA pre-approval and processed the enhanced application in 12 working days. The “qualified person” requirement was satisfied by hiring a Shanghai-based regulatory affairs specialist with 8 years of NMPA experience. Her onboarding documents — degree certificate (药学学士, Bachelor of Pharmacy), pharmacist license, and employment contract — were submitted as part of the AMR package.
- NMPA registration certificate transfer (Days 63–72): MediLyon’s 12 existing NMPA registration certificates were held by their Chinese distributor. Transferring them to the new WFOE required a separate NMPA application — the registration certificate holder change procedure (注册证变更, zhùcè zhèng biàngēng). This took 7 working days and cost RMB 18,000 ($2,480) in regulatory service fees.
- Tax registration and bank account (Days 73–87): Tax registration in Shanghai’s Pudong New Area took 4 working days. The corporate bank account at ICBC — requiring not just the legal representative’s video verification but also the qualified person’s in-person verification — took 10 working days. This was the only stage where a team member needed to be physically present in China, and it was the qualified person (the Shanghai-based hire), not the foreign CEO.
Results
Total registration cost: legal and regulatory service fees (RMB 128,000 / $17,620), NMPA pre-approval and certificate transfer fees (RMB 28,000 / $3,860), qualified person first-month salary and recruitment fee (RMB 62,000 / $8,540), government fees (RMB 1,800 / $248), and office deposit (RMB 36,000 / $4,960 for 3 months in Zhangjiang Hi-Tech Park). Grand total: approximately $35,230 — roughly 3.8× the cost of a general WFOE registration.
The timeline comparison is stark: a general WFOE in Shanghai averages 45–55 working days (per our WFOE registration guide). A medical device WFOE in the same city averaged 87 working days. The difference — 32–42 extra working days — came entirely from the NMPA pre-approval gate and the enhanced AMR documentation requirements.
For comparison, an in-person registration attempt would have cost MediLyon roughly $28,600: round-trip business-class flights Lyon–Shanghai ($5,800), 28 nights of serviced apartment rental ($4,200), and an estimated 120 hours of executive time at €150/hour ($18,600). The remote path with a specialized Shanghai law firm cost $35,230 — about $6,600 more — but eliminated travel logistics and delivered a predictable 87-day timeline with zero founder displacement.
The NMPA certificate transfer created immediate operational value: within 45 days of transfer completion, MediLyon submitted bids in 3 provincial hospital tenders (Zhejiang, Jiangsu, and Guangdong) that had been closed to them as a distributor-held certificate holder. Two of the three tenders were won, representing an estimated €1.4 million in annual recurring revenue — revenue the company could not have accessed without a locally held NMPA registration certificate. Our Negative List FAQ covers the full list of restricted sectors and the additional approvals each one requires.
Lessons Learned
1. Engage a sector-specific firm, not a general agency. The general corporate services agency MediLyon initially consulted quoted RMB 38,000 ($5,240) and “60–75 working days” — both of which proved to be fantasy numbers when the NMPA pre-approval requirement was factored in. A sector-specific firm costs 3× more, but the timeline they quote is the timeline you’ll actually get.
2. The “qualified person” requirement is a first-year cost that compounds. At RMB 35,000–50,000/month, the regulatory hire adds $58,000–$83,000 to year-1 costs. But this person is not dead weight — they handle NMPA renewals, adverse event reporting, labeling updates, and inspection preparation. Without them, the WFOE risks non-compliance penalties of RMB 50,000–200,000 ($6,900–$27,600) per violation. Budget the hire as compliance insurance, not overhead.
3. The NMPA certificate transfer is a regulatory process, not a clerical one — and it has its own failure modes. MediLyon’s transfer succeeded because their distributor cooperated. In cases where the distributor refuses to release certificates (common when the foreign company is transitioning away from the distribution relationship), the process requires a contested transfer application that adds 20–30 working days and legal costs of RMB 30,000–60,000 ($4,100–$8,300). If you’re terminating a distributor relationship, factor this risk into your registration timeline.
4. Shanghai’s NMPA pilot program is a genuine accelerator — but it only covers Shanghai. MediLyon’s 26-working-day NMPA review in Shanghai was 10–15 days faster than the national average. If they had registered in Beijing or Guangzhou, the NMPA pre-approval alone would have consumed 35–45 working days, pushing the total timeline past 100 days. For medical device companies evaluating locations, the presence of a local NMPA pilot office should be weighted as heavily as tax incentives or rental costs.
According to NMPA 2025 annual data, 312 foreign medical device manufacturers hold active registration certificates in China. The average time from application to certificate issuance for Class II devices was 127 working days in 2025, up from 118 in 2024 — a reflection of NMPA’s increasingly stringent clinical data requirements. Companies planning a China medical device entity should model a 130-working-day NMPA timeline as the baseline scenario, not the best case.
— China Gateway 360 —
Remote China market entry support, built around execution.
